Chugai Pharmaceutical : Organizational and Personnel Changes

Organizational and Personnel Changes

TOKYO, November 21, 2022 --Chugai Pharmaceutical Co., Ltd.(TOKYO: 4519) announced the following organizational and personnel changes, effective January 1, 2023.

[Details of Organizational Changes]

1. Establishment of ASPIRE Transformation Dept.

ASPIRE* Transformation Dept. will be newly established to implement the next-generation core business infrastructure (ERP: enterprise resource planning system) and to conduct company-wide reforms of business process and organizations.

• • ASPIRE Transformation Dept. will be newly established.
• ASPIRE: The name of a business and digital transformation program that will deliver cutting edge global standard processes and the next- generation ERP platforms across Chugai Group
  2. Establishment of Risk & Compliance Dept. and dissolution of Sustainability Dept.

In order to enhance the governance, Chugai will integrate the risk management and compliance promotion functions (including information management), which have been distributed within the company, to improve the effectiveness and efficiency. Organizational reforms of the corporate functions will be in place, including the establishment of Risk & Compliance Dept. and the dissolution of Sustainability Dept. Human Resources Management Dept. will be responsible for environmental protection and other EHS initiatives that have been driven by Sustainability Dept. At the same time, Chugai will continue its company-wide efforts for sustainability.

• Risk & Compliance Dept. will be newly established.
• Sustainability Dept. will be dissolved.
• The risk management and compliance promotion functions will be transferred to Risk & Compliance Dept. from General Affairs Dept., Sustainability Dept., Legal Dept., Business Strategy & Compliance Dept., and Corporate Planning Dept.
• Sustainability Dept.'s functions will be transferred: the EHS function to Human Resources Management Dept., and the social contribution function to General Affaires Dept.

3. Reorganization of Research Div.

The company will conduct organizational reforms to improve the success rate of drug discovery and the research productivity. The reforms aim to clarify the scope of responsibilities in accordance with technology areas and to enhance drug discovery technologies and digital infrastructures, as well as dealing with the diversification of approaches for drug discovery. For this purpose, Modality Technology Dept. and Biological Technology Dept. will be established, and Discovery Technology Dept. will be dissolved.

• Modality Technology Dept. will be newly established.
• Biological Technology Dept. will be newly established.
• Discovery Technology Dept. will be dissolved.

4. Reorganization of Translational Research Div. and Research Div.

The name and missions of Non-clinical Safety Assessment Dept. of Translational Research Div. will be changed to pursue a high-level human prediction, in addition to existing responsibilities that includes safety research, drug discovery research and integrated safety risk assessments with clinical and non- clinical information. Non-clinical Safety Assessment Dept. will be renamed Safety and Bioscience Research Dept., and its pharmacology documentation function will be transferred to Discovery Pharmacology Dept. of Research Div.

• Non-clinicalSafety Assessment Dept. will be renamed Safety and Bioscience Research Dept.
• The pharmacology documentation function of Non-clinical Safety Assessment Dept. will be transferred to Discovery Pharmacology Dept. of Research Div.

5. Reorganization of Medical Affairs Div.

In order to realize more advanced and specialized Medical Affairs (MA) functions including evidence generation activities, the company integrated Medical Liaison Dept. and Medical Science Dept. Also, organizational changes will be implemented to enable the planning and execution of medical strategies by specialized areas. Oncology Medical Science Dept. and Specialty Medical Science Dept. will be established while Medical Science Dept. and Medical Liaison Dept. will be dissolved. In addition, the medical information provision management functions that have been dispersed across multiple organizations will be integrated in Medical Information Dept.

• Oncology Medical Science Dept. will be newly established.
• Specialty Medical Science Dept. will be newly established.
• Medical Science Dept. will be dissolved.
• Medical Liaison Dept. will be dissolved.
• The medical information provision management functions will be integrated in Medical Information Dept.

[Details of Personnel Changes]

Directors

Name	New Responsibilities	Current Responsibilities
Osamu Okuda	Representative Director, President	Representative Director, President
	Chief Executive Officer (CEO)	Chief Executive Officer (CEO)
	Supervisory responsibility for	Supervisory responsibility for
	Corporate Planning, Partnering,	Corporate Planning, Partnering,
	External Affairs and Audit	External Affairs and Audit
	In charge of Corporate Planning	In charge of Corporate Planning
	Dept., ASPIRE Transformation	Dept., Partnering Dept., External
	Dept., Partnering Dept., External	Affairs Dept., and Audit Dept.
	Affairs Dept., and Audit Dept.
Toshiaki Itagaki	Director, Executive Vice President	Director, Executive Vice President
	Chief Financial Officer (CFO)	Chief Financial Officer (CFO)
	Supervisory responsibility for	Supervisory responsibility for
	Finance & Accounting, Corporate	Finance & Accounting, Corporate
	Communication and Procurement	Communication and Procurement
		Head of Finance Supervisory Div.

2/ 5

Executive Officers

Name	New Responsibilities	Current Responsibilities
Tetsuya	Executive Vice President	Executive Vice President
Yamaguchi	Supervisory responsibility for	Supervisory responsibility for
	Project & Lifecycle Management	Project & Lifecycle Management
	(Marketing), Drug Safety, Medical	(Marketing), Drug Safety, Medical
	Affairs and Foundation Medicine	Affairs and Foundation Medicine
	Head of Project & Lifecycle	Head of Project & Lifecycle
	Management Unit and Head of	Management Unit
	Foundation Medicine Unit
Yoshiyuki Yano	Executive Vice President	Executive Vice President
	Supervisory responsibility for	Supervisory responsibility for
	Human Resource Management	Human Resource Management
	and EHS	and EHS
	In charge of Human Resources	Head of Human Resources
	Management Dept.	Management Dept.
			In charge of Sustainability Dept.
Iwaaki Taniguchi	Senior Vice President	Senior Vice President
	Head of Finance Supervisory Div.	Head of Finance & Accounting
	and Head of Finance & Accounting	Dept.
	Dept.
Minoru Watanabe	Special Mission for CEO	Vice President
			Head of Drug Safety Div. and
			Head of Foundation Medicine Unit
Kaori Ouchi	Vice President	Vice President
	Head of Drug Safety Div.	Head of Medical Affairs Div.
Masayoshi Higuchi	Vice President	Vice President
	Head of Quality & Regulatory	Head of Quality & Regulatory
	Compliance Unit	Compliance Unit
	In charge of Risk & Compliance
	Dept.
Division Heads and Department Heads
Name	New Responsibilities		Current Responsibilities
Himiko Endo	Head of ASPIRE Transformation		Head of ASPIRE Program
	Dept.		Management Group, Corporate
			Planning Dept.
Akira Nishimura	Head of Risk & Compliance Dept.		Head of Strategic Planning Group,
			Corporate Planning Dept.
Yusuke Takada	Head of Human Resources		Head of HR Planning Group,
	Management Dept.		Human Resources Management
			Dept.

3/ 5

Division Heads and Department Heads (continued)

Name	New Responsibilities	Current Responsibilities
Takuya Torizawa	Head of Protein Science Dept.	Head of Protein Science Group 2,
	and Head of Protein Science	Protein Science Dept., Research
	Group 3, Research Div.	Div.
Atsushi Ohta	Head of Modality Technology	Head of Chemical Biotechnology
	Dept. and Head of Chemical	Group, Discovery Technology
	Biotechnology Group, Research	Dept., Research Div.
	Div.
Souhei Ohyama	Head of Biological Technology	Head of Immunology Group 2,
	Dept., Research Div.	Discovery Pharmacology Dept.,
		Research Div.
Hiromi Suzuki	Head of Safety and Bioscience	Head of Non-clinical Safety
	Research Dept., Translational	Assessment Dept., Translational
	Research Div.	Research Div.
Michiaki Tanaka	Head of Project Planning &	President & CEO of Chugai
	Coordination Dept., Translational	Pharma USA, Inc.
	Research Div.
Kentaro Kishi	Head of Marketing & Sales	Head of Targeted Disease Strategy
	Planning Dept., Project &	Group, Specialty Lifecycle
	Lifecycle Management Unit	Management Dept., Project &
		Lifecycle Management Unit
Kazumitsu Kanatani	Head of Digital Strategy Dept.,	Head of Insight Business Group,
	Digital Transformation Unit	Science and Technology Dept.,
		Project & Lifecycle Management
		Unit
Kazuhiko Nishi	Head of Medical Affairs Div.	Chugai Pharma Europe, Ltd.
		(Head of Commercial)
Yoshiaki Isshiki	Head of Medical Affairs Planning	Head of Medical Information Dept.
	Dept., Medical Affairs Div.	and Head of Medical Information
		Management Group, Medical
		Affairs Div.
Kenji Morita	Head of Medical Information	Head of Information Insight
	Dept., Medical Affairs Div.	Development Group 3, Medical
		Information Dept., Medical Affairs
		Div.
Mika Matsuzawa	Head of Oncology Medical	Head of Oncology DAS Group 1,
	Science Dept., Medical Affairs Div.	Oncology Lifecycle Management
		Dept., Project & Lifecycle
		Management Unit

4/ 5

Division Heads and Department Heads (continued)

Name	New Responsibilities	Current Responsibilities
Takuya Nakagawa	Head of Specialty Medical	Head of Medical Science Dept.,
	Science Dept., Medical Affairs Div.	Medical Affairs Div.
Kazuhisa Ohba	Head of Wholesaler Business	Head of Planning Group,
	Planning Dept., Marketing &	Wholesaler Business Planning
	Sales Div.	Dept., Marketing & Sales Div.
Takahiko Inoue	Head of Tokai & Hokuriku	Deputy Head of Oncology
	Regional Management Office,	Marketing Dept., Marketing & Sales
	Marketing & Sales Div.	Div.

###

5/ 5